NCT04015661

Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC

Status unknown Phase 2 Last updated 11 July 2019

What this trial tests

Phase 2 trial testing Nab-paclitaxel in Nasopharyngeal Carcinoma in 92 participants. Status unknown.

Timeline

9 July 2019

Primary endpoint
1 December 2020

1 June 2022

Quick facts

Lead sponsor	Fuzhou General Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	92
Start date	9 July 2019
Primary completion	1 December 2020
Estimated completion	1 June 2022
Sites	1 location across China

Drugs / interventions tested

• Nab-paclitaxel (nab-paclitaxel) — full drug profile →

Conditions studied

• Nasopharyngeal Carcinoma — all drugs for Nasopharyngeal Carcinoma →

Sponsor

Fuzhou General Hospital

Who can join

Adults 18 to 75, any sex, with Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nasopharyngeal carcinoma (NPC) is a malignant tumor that originates in nasopharyngeal epithelial cells. It is common in southern China and Southeast Asia, but the incidence rate is low in most parts of the world. According to the World Health Organization survey, 80% of nasopharyngeal carcinomas occur in China, with high incidence in southern China, as high as 30-50/100,000, such as Guangdong, Guangxi, Hunan, and Fujian. In 2015, Chinese cancer statistics showed that there were about 60,600 new cases of nasopharyngeal carcinoma in China, and the number of deaths was about 34,100. Radiation therapy is the main treatment for nasopharyngeal carcinoma. Early stage I and IIa achieved a 5-year survival rate (OS) of 90% and 84%, respectively . However, the treatment outcomes of most patients with locally advanced nasopharyngeal carcinoma are not ideal.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.